Table 1.
Completed clinical trials using MSC transplantation to treat chronic liver diseasesa
| Liver disease | No. of patients | Source | Cell type/hepatocyte-like cells | Delivery route | Main results | Country | Source |
|---|---|---|---|---|---|---|---|
| Decompensated liver cirrhosis | 4 | Iliac crest | Autologous MSCs/no | Cubital vein of the arm | Improvements in MELD score and serum creatinine level (6–12 mon after transplantation) | Iran | Mohamadnejad et al. [73] (2007) |
| Liver cirrhosis (4 HBV, 1 HCV, 1 alcoholic, and 2 cryptogenic) | 8 | Iliac crest | Autologous MSCs/partial | Peripheral and portal veins | Improvement in MELD score (24 wk after transplantation) | Sweden | Kharaziha et al. [74] (2009) |
| End-stage liver failure due to chronic HCV infection | 20 | Iliac crest | Autologous MSCs/yes | Intrasplenic (10) and intrahepatic (10) | Improvements in child and MELD scores (noted at 2 wk and maintained for 6 mon after transplantation) | Egypt | Amer et al. [75] (2011) |
| Liver failure due to chronic HBV infection | 53 | Iliac crest | Autologous MSCs/no | Proper hepatic artery | Improvement in MELD score (2–3 wk after transplantation) | China | Peng et al. [80] (2011) |
| HCV-related liver cirrhosis | 15 | Iliac crest | Autologous MSCs/both | Peripheral vein | Improvements in MELD score and serum albumin level (3 and 6 mon after transplantation) | Egypt | El-Ansary et al. [78] (2012) |
| Chronic HBV infection | 31 | Umbilical cord | Allogeneic MSCs/no | Peripheral vein | Improvements in MELD score, ascites, hyaluronic acid, procolla gen type III and type IV collagen (up to 48 wk after transplantation) | China | Zhang et al. [77] (2012) |
| Post-HCV liver cirrhosis | 20 | Iliac crest | Autologous MSCs/no | Intrasplenic injection | Improvements in MELD score and serum albumin level (24 wk after transplantation) | Egypt | Amin et al. [76] (2013) |
| Alcoholic liver cirrhosis | 11 | Iliac crest | Autologous MSCs/no | Right hepatic artery | Improvements in MELD score and liver histology (12 wk after transplantation) | Korea | Jang et al. [79] (2014) |
MSC, mesenchymal stem cell; MELD, Mayo End-Stage Liver Disease; HBV, hepatitis B virus; HCV, hepatitis C virus.
a
The data found by a search on www.clinicaltrials.gov (October 2014) with the terms “mesenchymal stem cells” and “liver cirrhosis.”